Furthermore, knockdown of ATG7 sensitized CML stem and progenitor cells to imatinib treatment via metabolic alterations in CML cells, increased production of reactive oxygen species, and increased differentiation of cells towards the erythroid lineage55 (Figure 1B). The gene discussed is ATG7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.